Operator Good day, and welcome to the OPKO Health third quarter of 2024 financial results conference call. All participants ...

We saw how the pandemic wrecked several industries’ balance sheets and supply chains ... based on their tracking of 50 GLP-1 drugs in development. However, the fund believes Eli Lilly and ...

We remain on track and look forward to top line 52-week ... We continue to strengthen our balance sheet with $2.5 billion of debt retired in the third quarter and expect to return to our pre ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...

As reported in August, the highest dose of tirzepatide tested—15 mg—also helped patients lose an average of 22.9% of their body weight, versus just 2.1% in the trial’s control arm. Patients ...

In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here ...

Findings at week 176 demonstrated that among prediabetic patients treated with tirzepatide (efficacy estimand; pooled doses of 5mg, 10mg, 15mg), 98.8% remained diabetes free. Detailed results were ...

When prescribing glucagon-like peptide 1 (GLP-1) medications, many physicians prefer tirzepatide over the more well-known semaglutide due to its superior efficacy in weight loss and A1c reduction.

Tirzepatide demonstrated sustained average weight loss of 22.9% (15 mg dose) through the three-year treatment period. The study showed an association of tirzepatide treatment with improved ...

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for treating pre-diabetic and obese individuals. Spanning 176 weeks of treatment ...